Thinking about what to do with your Travere Therapeutics stock? You are not alone. The past few months have been busy for this biotech name, giving investors new reasons to pay attention. Maybe you ...

SAN DIEGO, October 23, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the ...

As the industry's competition in the rare kidney disease IgA nephropathy (IgAN) heats up in the U.S., Roche’s Chugai Phar | Last year, Japan's Renalys picked up certain Asian rights to the IgAN ...

Thursday's IBD 50 Growth Stocks To Watch pick, biotech leader Travere Therapeutics TVTX, is approaching its latest buy point ...

Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, ...

The International Luxury Hotel Association (ILHA) has unveiled the full agenda for INSPIRE Europe 2025, taking place November 12?13 at the Congress Centre of the Czech National Bank in Prague. The two ...

First Trust Small Cap Growth AlphaDEX® Fund ETF has a unique sector mix and strong performance vs. peers. See more on FXC ETF ...

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...

The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic ...

Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.